
IBRX Stock Price Live, Key Points and Company Profile
IBRX Stock Price
IBRX Stock Price Live – Here
IBRX Company Profile
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company’s platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme.
Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.
IBRX Stock Price FAQs
What’s the current market cap for ImmunityBio stock?
What is the P/E ratio for ImmunityBio stock?
Does ImmunityBio stock pay dividends?
No, ImmunityBio (IBRX) stock does not pay dividends to its shareholders as of May 20, 2024.
When is the next ImmunityBio dividend payment date?
ImmunityBio (IBRX) stock does not pay dividends to its shareholders.
What is the beta indicator for ImmunityBio?
ImmunityBio (IBRX) has a beta rating of 0.93. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
What is the ImmunityBio stock price target?
The target price for ImmunityBio (IBRX) stock is $7.5, which is 1.96% below the current price of $7.65. This is an average based on projections from 2 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice – Lightyear does not carry out investment research.
What was ImmunityBio’s price range in the past 12 months?
What is ImmunityBio’s market cap?
When is ImmunityBio’s upcoming earnings report date?
How were ImmunityBio’s earnings last quarter?
Is ImmunityBio overvalued?
Does ImmunityBio pay dividends?
What is ImmunityBio’s EPS estimate?
How many shares outstanding does ImmunityBio have?
What happened to ImmunityBio’s price movement after its last earnings report?
Which hedge fund is a major shareholder of ImmunityBio?
What is the current share price of Immunitybio Inc (IBRX)?
The share price of Immunitybio Inc (IBRX) is $7.65 (NASDAQ) as of 17-May-2024 16:12 EDT. Immunitybio Inc (IBRX) has given a return of -20.33% in the last 3 years.
What is the market cap of Immunitybio Inc (IBRX)?
Immunitybio Inc (IBRX) has a market capitalisation of $ 5,291 Mln as on 17-May-2024. As per Value Research classification, it is a Small Cap company.
How can you buy shares of Immunitybio Inc (IBRX)?
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Immunitybio Inc (IBRX) and enter the required number of quantities and click on buy to purchase the shares of Immunitybio Inc (IBRX).
What is the main business of Immunitybio Inc (IBRX)?
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company’s platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme.
Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.
Who are the promoters/managers of Immunitybio Inc (IBRX)?
The CEO & director of Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.Sc.. is Immunitybio Inc (IBRX), and CFO & Sr. VP is Mr. Richard Gerald Adcock.
What is the total promoter pledging in Immunitybio Inc (IBRX)?
There is no promoter pledging in Immunitybio Inc (IBRX).
Read our More Articles
- Sunrun Stock Price Chart, Overview, Stats, Company Profile
- NVTA Stock Forecast 2025/Invitae Corp Stock Price Forecast for 2025
One thought on “IBRX Stock Price Live, Key Points and Company Profile”